A
Anokion
Harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance
About Anokion
Anokion is a cutting-edge biotechnology startup that operates in the healthcare sector, specifically in the treatment of autoimmune diseases. The company's primary focus is on developing a more effective approach to treating these diseases by leveraging its proprietary immune tolerance platform. This platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy. Unlike traditional treatments that often come with a host of side effects due to broad immunosuppression, Anokion's approach is designed to avoid these side effects.
The company's platform can be applied to virtually any antigen-mediated disease, indicating a broad market potential across various clinical applications. Essentially, Anokion's business model revolves around the development and commercialization of these innovative therapies. The company makes money by selling these therapies to healthcare providers who then administer them to patients suffering from autoimmune diseases.
Anokion's approach is unique in that it harnesses the body's natural tolerance pathways to target disease-causing antigens, thereby transforming the way autoimmune therapy is conducted. This positions the company well in the growing market for autoimmune disease treatments, which is driven by an increasing global prevalence of these diseases.
In summary, Anokion is a biotech startup that develops and sells innovative, targeted therapies for autoimmune diseases, leveraging its proprietary immune tolerance platform and the body's natural tolerance pathways.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- Cambridge, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 65.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Sep 2019
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2022 | $35M | $200M | Pfizer | ↗ |
| SERIES BOther financing | Sep 2019 | $40M | $160M | Novo Ventures · Novartis Venture Fund · Versant Ventures | ↗ |
Growth signals
Latest recorded traffic for Anokion is 200 monthly website visits, down 91.7% over the last three months. Anokion's team declined 64.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Fondation FIT
Series A3 investors entered at this stage
Versant Ventures
Novartis Venture Fund
Novo Ventures
Series B and later1 investor entered at this stage
Pfizer
Other known investors2 additional known investors
Celgene
EPFL Swiss Federal Polytechnic School of Lausanne
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anokion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anokion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.